NASDAQ : PGEN
Precigen, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 6.94 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.48B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.48B |
| Enterprise Value | 2.54B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 358.04M |
| Shares Outstanding | 358.04M |
| Shares Change (YoY) | +18.38% |
| Shares Change (QoQ) | +16.76% |
| Owned by Insiders (%) | 11.71% |
| Owned by Institutions (%) | 39.41% |
| Float | 194.60M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 12.42 |
| PS Ratio | 28.99 |
| Forward PS | 7.77 |
| PB Ratio | 57.02 |
| P/TBV Ratio | 96.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 29.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.58 |
| Quick Ratio | 3.76 |
| Debt / Equity | 2.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.06 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -837.08% |
| Return on Assets (ROA) | -18.14% |
| Return on Invested Capital (ROIC) | -34.97% |
| Return on Capital Employed (ROCE) | -28.02% |
| Weighted Average Cost of Capital (WACC) | 9.58% |
| Revenue Per Employee | $535,731 |
| Profits Per Employee | -$2.10M |
| Employee Count | 160 |
| Asset Turnover | 0.63 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.98 |
| 52-Week Price Change | +73.07% |
| 50-Day Moving Average | 7.22 |
| 200-Day Moving Average | 5.27 |
| Relative Strength Index (RSI) | 50.29 |
| Average Volume (20 Days) | 4,878,725 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 46.39M |
| Short Previous Month | 47.55M |
| Short % of Shares Out | 12.96% |
| Short % of Float | 23.84% |
| Short Ratio (days to cover) | 8.53 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 85.72M |
| Gross Profit | 45.44M |
| Operating Income | -39.50M |
| Pretax Income | -157.71M |
| Net Income | -336.71M |
| EBITDA | -35.36M |
| EBIT | -39.50M |
| Loss Per Share | -$0.98 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 38.21M |
| Total Debt | 98.35M |
| Net Cash | -60.14M |
| Net Cash Per Share | -$0.17 |
| Equity (Book Value) | 43.58M |
| Book Value Per Share | 0.12 |
| Working Capital | 105.03M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -114.17M |
| Capital Expenditures | -1.06M |
| Depreciation & Amortization | 4.14M |
| Net Borrowing | 92.82M |
| Free Cash Flow | -115.22M |
| FCF Per Share | -$0.32 |
Margins
| Measure | Value |
|---|
| Gross Margin | 53.01% |
| Operating Margin | -46.08% |
| Pretax Margin | -183.98% |
| Profit Margin | -183.98% |
| EBITDA Margin | -41.25% |
| EBIT Margin | -46.08% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -18.38% |
| Shareholder Yield | -18.38% |
| Earnings Yield | -14.17% |
| FCF Yield | -4.64% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $13.65 |
| Price Target Difference | 96.69% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 275.44% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -12.66 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |